Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 87, Issue 5, 1999, Pages 544-551

  Loury, David J ^a   Embree, Jay R ^a   Steinberg, Deborah A ^a   Sonis, Stephen T ^b   Fiddes, John C ^a  

^a IntraBiotics Pharmaceuticals Inc   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL PEPTIDE IB 367; ANTIMICROBIAL PEPTIDE IB-367; FLUOROURACIL; PEPTIDE; PEPTIDE FRAGMENT; PROTEIN; TOPICAL ANTIINFECTIVE AGENT;

ANIMAL; ARTICLE; BACILLUS; BACTERIAL COUNT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; ESCHERICHIA COLI; HAMSTER; MALE; MICROBIOLOGY; MOUTH MUCOSA; NONPARAMETRIC TEST; PASTEURELLA; PROTEUS MIRABILIS; STOMATITIS; STREPTOCOCCUS; SYRIAN HAMSTER;

ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; BACILLUS; COLONY COUNT, MICROBIAL; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ESCHERICHIA COLI; FLUOROURACIL; MALE; MESOCRICETUS; MOUTH MUCOSA; PASTEURELLA; PEPTIDE FRAGMENTS; PEPTIDES; PROTEINS; PROTEUS MIRABILIS; STATISTICS, NONPARAMETRIC; STOMATITIS; STREPTOCOCCUS;

EID: 0033124110     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1079-2104(99)70131-9     Document Type: Article

References (32)

1. Rosenberg SW. Oral complications of cancer chemotherapy: a review of 398 patients. J Oral Med 1986;41:93-7.
2. Carl W. Oral complication of local and systemic cancer treatment. Curr Opin Oncol 1995;7:320-4.
3. Symonds RP, McIlroy P, Khorrami J, Paul J, Pyper E, Alcock SR, et al. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. Br J Cancer 1996;74:312-7.
4. Caballero GA, Austrian RK, Quebbeman EJ. Long-term, ambulatory continuous iv infusion of 5-U for the treatment of advanced adenocarcinomas. Cancer Treatment Reports 1985;69:13-5.
5. Balis FM, Savitch JL, Bleyer WA. Remission induction of menigeal leukemia with high-dose intravenous methotrexate. J Clin Oncol 1985;3:485-9.
6. Roth BJ, Sledge GW Jr. Williams SD, Meyer SC, Ansari R, Fisher WB. Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. Cancer 1991;68:248-52.
7. Bishop JF, Joshua DE, Lowenthal RM, Kronenberg H, Whiteside MG, Cobcroft R. A phase I-II study of cytosine arabinoside, daunorubicin, and VP16-213 in adult patients with acute non-lymhocytic leukemia. Aust N Z J Med 1986;16:48-51.
8. National Institutes of Health. Oral complications of cancer therapies: diagnosis, prevention, and treatment: NIH Consens Devel Conf Statement. 1989;7:1-14.
9. Sonis ST. Oral complications of cancer therapy. In: DeVitta V, Hellman S, Rosenberg SA, editors. Principles and practices of oncology. Philadelphia: JB Lippincott; 1993. p. 2385-94.
10. Bochud PY, Eggiman Ph, Calandra TH, Van Melle G, Saghafi L, Francioloi P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1995;20:469-70.
11. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, Granena A, Gudiol F. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis 1996;15:291-6.
12. Case DC Jr, Gams R, Ervin TJ, Boyd MA, Oldham FB. Phase III trials of high dose epirubicin in patients with lymphoma. Cancer Res 1987;47:6393-6.
13. Brincker H, Christensen BE. Acute mucocutaneous toxicity following high-dose hydroxyurea. Cancer Chemother Pharmacol 1993;32:496-7.
14. Lokich J, Anderson N, Bern M, Coco F, Zipoli T, Moore C, et al. Dual modulation of 5-fluorouracil using leuconvorin and hydroxyurea. Cancer 1991;68:744-6.
15. Guggenheimer J, Verbin RS, Appel BN, Schmutz J. Clinicopathologic effects of cancer chemotherapeutic agents on human buccal mucosa. Oral Surg Oral Med Oral Pathol 1977;44:58-63.
16. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncology 1998;34:39-43.
17. Bernhoft CH, Skaug N. Oral findings in irradiated edentulous patients. Int J Oral Surg 1985;14:416-27.
18. Verdi CJ. Cancer therapy and oral mucositis: an appraisal of drug prophylaxis. Drug Safety 1993;9:185-95.
19. Kokryakov VN, Harwig SS, Panyutich EA, Shevchenko AA, Aleshina GM, Shamova OV, et al. Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. FEBS Lett 1993;327:231-6.
20. Zhao C, Ganz T, Lehrer RI. The structure of porcine protegrin genes. FEBS Lett 1995;368:197-02.
21. Zhao C, Liu L, Lehrer RI. Identification of a new member of the protegrin family by cDNA cloning. FEBS Lett 1994;346:285-8.
22. Harwig SS, Swiderek KM, Lee TD, Lehrer RI. Determination of disulphide bridges in PG-2, an antimicrobial peptide from porcine leukocytes. J Pept Sci 1995;1:207-15.
23. Aumelas A, Mangoni M, Roumestand C, Chiche L, Despaux E, Grassy G, et al. Synthesis and solution stucture of the antimicrobial peptide protegrin-1. Eur J Biochem 1996;237:575-83.
24. Steinberg DA, Hurst MA, So W, Viajar BSC, Fujii CA. IB-367: a protegrin peptide with rapid microbicidal activity against the flora associated with oral mucositis (37th International Conference). Antimicrob Agents Chemother 1997;154.
25. Sonis ST, Tracey C, Shklar G, Jenson J, Florine D. An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol 1990;69:437-43.
26. Weisdorf DJ, Bostrom B, Raether D, Mattingly M, Walker P, Pihlstrom B, et al. Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouth rinse. Bone Marrow Transplant 1989;4:89-95.
27. Sonis S, Muska A, O'Brien J, Van Vugt A, Langer-Safer P, Keith J. Alteration in the frequency, severity and duration of chemotherapy-induced mucositis in hamsters by interleukin-11. Eur J Cancer B Oral Oncol 1995;31:261-6.
28. Sonis ST, Van Vugt AG, Brien JP, Muska AD, Bruskin AM, Rose A, et al. Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. Oral Oncol 1997;33:47-54
29. Ferretti GA, Ash RC, Brown AT, Parr MD, Romond EH, Lillich TT. Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplant 1988;3:483-93.
30. Epstein JB, Vickars L, Spinelli J, Reece D. Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1992;73:682-9.
31. Foote RL, Loprinzi CL, Frank AR, O'Fallon JR, Gulavita S, Tewfik HH, et al. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation induced mucositis. J Clin Oncol 1994;12:2630-3.
32. Spijkervet FK, Van Saene HK, Van Saene JJ, Panders AK, Vermey A, Mehta DM, et al. Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients. J Surg Oncol 1991;46:167-73.